Related Experiment Video
Updated: Jun 5, 2026
11:11
Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment
Published on: January 24, 2020
Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients
Jing-Ting Jiang1, Yue-Ping Shen, Chang-Ping Wu
1Key Laboratory of Stem Cell of Jiangsu Province, Institute of Biotechnology, Key Laboratory of Clinical Immunology of Jiangsu Province, Soochow University, Suzhou 215123, Jiangsu Province, China.
World Journal of Gastroenterology
|December 25, 2010
Summary
Cytokine-induced killer (CIK) cell adoptive immunotherapy significantly improves survival in gastric cancer patients compared to chemotherapy alone. Increasing CIK cell treatment frequency further enhances patient benefits and reduces mortality risk.
Area of Science:
- Immunology
- Oncology
- Gastroenterology
Background:
- Gastric cancer remains a leading cause of cancer-related death worldwide.
- Current treatments, including chemotherapy, have limitations in improving long-term survival.
- Adoptive immunotherapy using cytokine-induced killer (CIK) cells presents a potential alternative or adjunct therapy.
Purpose of the Study:
- To analyze the correlation between CIK cell adoptive immunotherapy and cancer-related death in gastric cancer patients.
- To compare the survival outcomes of gastric cancer patients treated with CIK cell therapy versus chemotherapy.
- To investigate the impact of CIK cell treatment frequency on patient survival.
Main Methods:
- A cohort of 156 gastric cancer patients post-operation was studied.
- Clinical data, including survival time and treatment outcomes, were collected.
- Kaplan-Meier method and Cox proportional hazards models were used for survival analysis.
Main Results:
- CIK cell adoptive immunotherapy resulted in significantly longer survival times compared to chemotherapy (median survival: 49 vs 27 months).
- 2- and 5-year survival rates were significantly higher in the CIK cell group (73.5% vs 52.6% and 40.4% vs 23.9%, respectively).
- Higher frequencies of CIK cell immunotherapy were associated with a reduced risk of death (HR=0.54).
Conclusions:
- Chemotherapy combined with CIK cell adoptive immunotherapy significantly prolongs survival in gastric cancer patients.
- Increasing the frequency of CIK cell adoptive immunotherapy appears to provide greater benefits to patients.
- CIK cell therapy holds promise as an effective treatment strategy for gastric cancer.
Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
01:26Gastritis II: Pathophysiology
The pathophysiology of gastritis begins with the colonization of the stomach lining by Helicobacter pylori (H. pylori). This bacterium spreads mainly via the oral-oral route through saliva or shared utensils, and can also be transmitted in overcrowded or unhygienic environments through contaminated water, despite its brief survival outside the body.ColonizationOnce ingested, H. pylori enters the stomach and begins colonization by navigating through the mucus layer lining the stomach wall. It...